Abstract
Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.
Keywords: Neuroendocrine tumors, biomarkers, somatostatin analogs, angiogenesis inhibitors, cytotoxic chemotherapy, radionuclide therapy, liver-targeted therapies.
Anti-Cancer Agents in Medicinal Chemistry
Title:Therapeutic Challenges in Neuroendocrine Tumors
Volume: 17 Issue: 7
Author(s): Ioannis Legakis*, Muhammad Wasif Saif and Kostantinos Syrigos
Affiliation:
- Oncology Unit, 3rd Department of Internal Medicine, Sotiria General Hospital, Athens School of Medicine, Athens,Greece
Keywords: Neuroendocrine tumors, biomarkers, somatostatin analogs, angiogenesis inhibitors, cytotoxic chemotherapy, radionuclide therapy, liver-targeted therapies.
Abstract: Neuroendocrine tumors (NETs) are a diverse set of tumors, being genetically varied. NETs can be presented with a distinct clinical picture, due to the production of various hormones, or being silent. Based on community health clinical statistics, the frequency numbers and reported occurrence of NETs are increasing. Although the therapeutic options for NETs have expanded in recent years, clinical diagnosis is possible only when metastases are present, requiring chronic complicated medical management. A positive development is that the recent evolution of molecularly-targeted therapy in oncology promotes the evolution of innovative tools for the management of these tumors. A diverse assortment of medical specialists is needed to improve outcomes and orchestrate the therapeutic care plan for NET patients.
Export Options
About this article
Cite this article as:
Legakis Ioannis*, Saif Wasif Muhammad and Syrigos Kostantinos, Therapeutic Challenges in Neuroendocrine Tumors, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520617666170213113401
DOI https://dx.doi.org/10.2174/1871520617666170213113401 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging The Medicinal Chemistry of Peptides
Current Medicinal Chemistry Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract
Current Molecular Pharmacology Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Preparation of Therapeutic Dose of <sup>177</sup>Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ‘In-situ’ Preparation at Hospital Radiopharmacy
Current Radiopharmaceuticals Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry